微粒化非诺贝特对Ⅱ型糖尿病高脂血症的疗效

Effect of Fenofibrate on Hyperlipidemia in NoninsulinDependent Diabetes Mellitus

目的观察微粒化非诺贝特对Ⅱ型糖尿病患者高脂血症的疗效及其安全性。方法对35例Ⅱ型糖尿病伴高脂血症患者予以口服微粒化非诺贝特（0．2g／d），共8周。结果微粒化非诺贝特能明显降低血清TG，TC，LDL－Ch，ApoB100（P均＜0．01），升高HDL－Ch（P＜0．01），且降低血尿酸与纤维蛋白原含量（P均＜0．01）。不良反应少而轻微。结论微粒化非诺贝特是调节Ⅱ型糖尿病患者血脂紊乱安全有效的药物。

Objective To evaluat the therapeutic effect and safety of fenofibrate on hyperlipidemia in NIDDM patients. Methods Thirty-five NIDDM patients with hyperlipidemia were treated with fenofibrate (0.2g/d) for 8wks. Res'lts After treatment for 8weeks TG, TC, LDL-Ch and ApoB100 declined and HDL-Ch increased significantly (P＜0.01). Fenofibrate also decreased serum urinary acid and fibrinogen. Adverse reactions were mild. Conclusion it suggests that fenofibrate is effective and safe in NIDDM patients with hyperlipidemia.